Alpaslan GÖKÇİMEN, Meltem ÖZGÜNER, DİLEK BAYRAM, Mehmet URAL, Osman SULAK

Metamizol sodyumun sıçan karaciğer, böbrek ve akciğer dokuları üzerine etkisi

Metamizol sodyum (MS) aminopirinin 4 - metilaminoetanosülfat türevi olup, dipiron olarak da bilinmektedir. Bir ön ilaç olması dolayısıyla, yapılan in-vitro çalışmalarda siklooksijenaz enzimini etkilemez. Bu çalışmada, kas içine verilen metamizolün sıçan karaciğer, akciğer ve böbrek dokuları üzerine ışık mikroskobu bazında etkileri araştırıldı. Çalışma grubundaki hayvanlara 5 gün boyunca günlük 200 mg dozda metamizol verildi ve her gün, bir gruptaki ikişer hayvan açıldı. Kontrol ve deney gruplarında 10.ar hayvan bulunmaktaydı. Eter anestezisi altında, hayvanlardan doku ve kan örnekleri alındı ve histopatolojik inceleme uygulandı. Kontrol ve deney grupları arasında, istatistiki yönden anlamlı bir farklılık yoktu. Dolayısıyla, buradan metamizolün veya benzeri steroid olmayan antienflamatuvar (NSAII) ilaçların kısa vadede güvenilir bir şekilde kullanılabileceği sonucuna ulaştık.

Anahtar Kelimeler:

Karaciğer, Böbrek, Akciğer, Sıçan, Wistar, Dipiron

Effects of metamizol sodium on liver, kidney and lung tissues of the rat

Metamizol sodium (MS) is a 4-methylaminoethansulphate derivative of aminopirine and also known as dipyrone. As it is a pro-drug, it does not affect cyclooxygenase enzyme during in vitro studies. In this study, effects of intramusculary administered metamizol were investigated. 200 mg / day metamizol was applied for 5 days and two animals from each group were decapitated on each day. There were 10 animals in both experiment and control groups. Tissues and blood samples were taken under ether anesthesia and histopatgological examination was performed. There was no statistically significant difference between the experiment and control groups. Thus, we have concluded that metamizol or similiar NSAI drugs may be used securely in short-term.

Keywords:

Liver, Kidney, Lung, Rats, Wistar, Dipyrone,

PDF

___

1. Kayaalp S.O. Tıbbi Farmakoloji. Hacettepe-Taş Kitapçılık Ltd. şti. 2000; Dokuzuncu Baskı. 1042-1043.
2. Shimada SG, Otterness IG, Stitt JT. A study of the mechanism of action of the mild analgesic dipyrone. Agents Actions 1994;41(3-4):188-92.
3. Giri AK, Mukhopadhyay A. Mutagenicity assay in salmonella and in vivo sister chromatid exchange in bone marrow cells of mice for four pyrazolone derivatives. Mutation Research. 1998; 420: 15-25.
4. Woodbury DM, Fingl E. Analgesic, antipyretic, anti-inflammatory agents and drugs employed in the therapy of gout, in: L.S. Goodman A.Gilman (EDS). The Pharmacological Basis of Therapeutics, Macmillan Publishing, New York. 1975; 334-39.
5. Greenstone M, Harhey B, Gabriel R, Bevan G. Acute nephrotic syndrome with reversible renal failure after phenylbutazone. Br. Med. J. 1981; 282: 950-951.
6. Chaplin S. Bone marrow depression due to mainser in, phenylbutazone,oxyphenylbutazone and chloramphenicol. Ad. Drug React. Acute poisoning Rev.1986; 5: 97-136.
7. Warsef NW. Teratogenicity of phenylbutazone in mice. Bull. Zool. Soc. Egypt. 1979;29: 16-21.
8. Schardein JL, Blatz AT, Woosley ET, Kaump DH.Reproduction studies on sodium meclofenamate in comparison to aspirin and phenylbutazone. Toxicol. Appl. Pharmacol. 1969; 15: 46-55.
9. Kari F, Bucher J, Haseman J, Euitis S, Huff J. Long-term exposure to the antiinflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Natl. Inst. Environ. Health Sci. 1995; 86: 252-263.
10.Klein W, Kocsis F, Scherer G, Altmann HZ. Experimantal effects of oxyphenylbutazone and prednisolone on the DNA matabolism in Syrian hamsters.Rheumatology. 1980; 39: 301-308.
11. Donaubauer H, Kief H, Kramer M, Krief K, Mayer D, Schuitz E. Investigations on the carcinogenicity of dipyrone in rats. Toxicol App Pharm.1985;81(3): 443-451.
12. Kramer M. Chronic toxicity of pyrazolones: the problem of nitrosation. British Journal of Clinical Pharmacology. 1980; 10(2): 313-317.
13.Maj S, Lis Y. The incidince of metamizole sodiuminduced agranulocytosis Poland.J. Int. Med. Res. 2002; 30(5): 488-95.
14. White WJ. The use of laboratory animals in toxicologic research. In: Principles and method of toxicology. (AW. Hayes. Ed). 4th ed. Taylor&Francis, Philadelphia. 2001 774-818.
15.Gökçimen A, Aydın G, Karaöz E, Malas MA, Öncü M. Effect of diclofenac sodium administration during pregnancy in the postnatal period. Fetal Diagn Ther. 2001; 16: 417-422.
16.Bar-Oz B, Clementi M, Di Giantonio E, Greenberg R, Beer M, Merlob P, Arnon J,Ornoy A, Zimmerman DM, Berkovitch M. Metamizol (dipyrone, optalgin) in pregnancy, is it safe ? A prospective comparative study. Eur J Obstet Gynecol Reprod Biol. 2005; 1:119 (2):176-9.
17.Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol. 2005; 60 (11): 821-9.
18.Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 2002; 58 (4): 265-274.
19.Farker K, Nassr N, Huck F, Zerle G, Rosenkranz B, Schmieder G, HoffmannA. Dipyrone and diclofenac do not influence creatinine-clearance, inulin-clearance or PAH-clearance in healthy male volunteers. Int J Clin Pharmacol Ther. 1995; 33(3):125-30.
20.Kumagai H, Kawaura A, Shibata M, Otsuka H. Carcinogenicity of dipyrone in (C57BL/6 X C3H)F1 mice. J Natl Cancer Inst. 1983; 71 (6): 1295-7.
21.Heinemeyer G, Gramm HJ, Roots I, Dennhardt R, Simgen W. The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction. Eur J Clin Pharmacol. 1993; 45 (5): 445-50.
22.Jaszczuk E, Graczyk M, Oszukowski P, Brzezinski P. Anaphylactic shock leading to death in a young woman after oral administration of metamizole (Pyralginum- Polfa)--case report. Przegl Lek. 1999; 56 (2): 175-6.